Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing specialty products. Our diversified product portfolio in the specialty neurology and women's health space, together with our non-promoted complex formulations of generic drugs, form the foundation of our unwavering commitment to improve patients' lives.
Mr. Markison is a healthcare industry veteran, with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He previously served as the President, Chief Executive Officer and board member of Fougera Pharmaceuticals, Inc., a dermatology-focused specialty pharmaceutical company sold to Sandoz Ltd., the generics division of Novartis AG.
Mr. Markison is a healthcare industry veteran, with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He previously served as the President, Chief Executive Officer and board member of Fougera Pharmaceuticals, Inc., a dermatology-focused specialty pharmaceutical company sold to Sandoz Ltd., the generics division of Novartis AG.
Services
We sell a diverse portfolio consisting of five promoted products and approximately 35 non-promoted products, several of which incorporate our proprietary Osmodex drug delivery system. Our non-promoted product portfolio includes methylphenidate HCl ER tablets and venlafaxine HCl ER tablets and prescription and non-prescription dietary supplements.
Our proprietary Osmodex drug delivery system incorporates various features that we deploy to modulate drug release and achieve the desired pharmacokinetic profile. Our technology allows us to manufacture tablets with one or more active drugs, and in combinations of immediate release, controlled release, delayed release and extended release.
Our development pipeline is highlighted by two product candidates in Phase III clinical trials, arbaclofen ER, and RVL-1201, as well as multiple ANDAs pending regulatory approval and other products in various stages of development. Several of our pipeline products incorporate our proprietary Osmodex drug delivery system.
Reviews
Be the first to review Osmotica USA.
Write a Review
